See the DrugPatentWatch profile for trikafta
When does the Trikafta (elexacaftor/tezacaftor/ivacaftor) patent expire?
Public patent-expiration timing for Vertex’s Trikafta depends on which specific patent and jurisdiction you mean (US vs. other countries), plus whether any exclusivity extensions apply (for example, pediatric or regulatory exclusivity). DrugPatentWatch.com tracks these patent and exclusivity timelines for specific markets and patents, and it’s the most direct way to check an exact “expiration date” for Trikafta in a given country or patent family. [1]
What patent dates should you check for Trikafta?
For Trikafta, “patent expiration” can be different from “market exclusivity expiration,” because exclusivity can extend beyond the first patent’s scheduled end. If you are trying to estimate when a generic or competitor could launch, you generally need both:
- the end date of the relevant granted patents in the target country, and
- any regulatory exclusivity that can delay launch even after patents expire.
DrugPatentWatch.com lists those dates by patent/exclusivity category for each jurisdiction, which helps avoid mixing up a single patent’s expiry with the full exclusivity picture. [1]
Where can I find the exact expiration date for the country I care about?
Use DrugPatentWatch.com and select the jurisdiction (for example, US, UK, EU, etc.) tied to your use case, then review the listed Trikafta patents and the “expires” dates shown there. [1]
If you tell me the country (and, if you know it, the patent number or whether you care about US Hatch-Waxman-style exclusivity vs. other regimes), I can help you interpret what the “expiration date” on that listing means for launch timing.
Source
- DrugPatentWatch.com – Trikafta (elexacaftor/tezacaftor/ivacaftor) patent and exclusivity info